Kelly succeeds Tom Burns, who is retiring and will become the executive chair of the board.
“We are all delighted to welcome Kevin as Resonetics’ next CEO. I’ve known Kevin for more than 20 years, and he brings a long track record of success in the medical technology industry, a customer-centric orientation, and a very collaborative leadership style,” Burns said in a news release. “He has all the attributes to ensure Resonetics will continue to lead the way with the innovative technologies and strong execution our customers require. I’d also like to thank Chip Hance for his mentorship over the past five years as executive chairman. He will continue to play an important role as an active member of the board.”
Kelly has more than 25 years of experience in the medical device industry. He has extensive global experience and diverse expertise in strategic planning, organizational development, business transformation, acquisition and integrations, according to Resonetics. Prior to joining the company, Kelly was president of BD’s surgery business unit, which is a $1.5 billion global business. He has also held numerous leadership roles at C.R Bard, SmartPill (acquired by Medtronic), LeMaitre Vascular and MedSource Technologies (now Integer).
“I am excited to be joining Resonetics at this pivotal time,” Kelly said. “The pending acquisition of the SAES Medical Nitinol business, combined with Resonetics’ robust organic growth, sound industry fundamentals, and strong financial backing, has the company well-positioned for future growth. I look forward to working with the Resonetics team, and our equity investors Carlyle and GTCR, to continue to build a best-in-class offering that will benefit our customers and patients worldwide.”
